No price history available.
Key financial summary
Financials in SEK| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM | 2027E | ||
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenue | SEKm | 14,601 | 13,763 | 14,548 | 16,869 | 18,119 | 18,016 | 16,718 | N/A | N/A |
| Operating profit | SEKm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net profit | SEKm | 1,084 | 1,254 | 1,154 | 943 | 1,302 | 237 | -520 | N/A | N/A |
| EPS reported | SEK | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating cashflow per share | SEK | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Capex per share | SEK | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF per share | SEK | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Free cash flow | SEKm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt | SEKm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value equity | SEKm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value per share | SEK | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Number of shares | m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| DPS (TTM paid) | SEK | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Financial summary
Financials in SEK| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM | 2027E | ||
|---|---|---|---|---|---|---|---|---|---|---|
| Value | ||||||||||
| P/E LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/B LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/S LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/FCF LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/EBITDA LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/Sales LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Earnings Yield LTM | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Quality | ||||||||||
| ROE | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| ROIC | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Sales | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Growth and momentum | ||||||||||
| EPS Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Sales Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Income Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating Profit Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend and capital structure | ||||||||||
| Dividend Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Payout Ratio | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Debt | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Debt/EBITDA | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EBIT/Net interest | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/market cap | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/Equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross debt/equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
Elekta AB (publ) operates as a global medical technology company, delivering advanced clinical solutions for managing cancer and various brain disorders. Its extensive oncology offerings include sophisticated radiation therapy systems such as Versa HD, tailored for brain metastases; the groundbreaking Elekta Unity, leveraging MR-Linac technology; linear accelerators like Elekta Harmony; and Elekta Infinity, designed to address diverse radiotherapy needs. The company also provides Elekta Synergy, a digital accelerator for advanced image-guided radiation therapy. Beyond primary treatment devices, Elekta supplies comprehensive treatment management solutions, automated and integrated quality assurance tools, and hardware/software for motion management. Specialized oncology platforms feature MOSAIQ Plaza for multidisciplinary cancer care, the managed hosting service Elekta Axis Cloud, and Elekta Studio for image-guided brachytherapy. Complementary hardware includes the ImagingRing mobile CT scanner. For brachytherapy, they offer smart tools like Oncentra Brachy to streamline repetitive tasks, alongside applicators such as Venezia and Geneva for cervical cancer treatment, and the Elekta Flexitron afterloader for precise workflow execution. In the field of neurosurgery and radiosurgery, Elekta provides the Leksell Gamma Knife series, including Icon for personalized radiation treatment, Perfexion as a vital tool for neurosurgeons, and Lightning for accelerated radiosurgery. Their neurosurgery product line further encompasses the Leksell Vantage Stereotactic System for intracranial procedures and the Leksell Stereotactic System for minimally invasive interventions. Elekta AB (publ) was founded in 1972 and is headquartered in Stockholm, Sweden.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Based on consensus from external analysts. Not Kvantra's opinion.
Elekta AB (publ) operates as a global medical technology company, delivering advanced clinical solutions for managing cancer and various brain disorders. Its extensive oncology offerings include sophisticated radiation therapy systems such as Versa HD, tailored for brain metastases; the groundbreaking Elekta Unity, leveraging MR-Linac technology; linear accelerators like Elekta Harmony; and Elekta Infinity, designed to address diverse radiotherapy needs. The company also provides Elekta Synergy, a digital accelerator for advanced image-guided radiation therapy. Beyond primary treatment devices, Elekta supplies comprehensive treatment management solutions, automated and integrated quality assurance tools, and hardware/software for motion management. Specialized oncology platforms feature MOSAIQ Plaza for multidisciplinary cancer care, the managed hosting service Elekta Axis Cloud, and Elekta Studio for image-guided brachytherapy. Complementary hardware includes the ImagingRing mobile CT scanner. For brachytherapy, they offer smart tools like Oncentra Brachy to streamline repetitive tasks, alongside applicators such as Venezia and Geneva for cervical cancer treatment, and the Elekta Flexitron afterloader for precise workflow execution. In the field of neurosurgery and radiosurgery, Elekta provides the Leksell Gamma Knife series, including Icon for personalized radiation treatment, Perfexion as a vital tool for neurosurgeons, and Lightning for accelerated radiosurgery. Their neurosurgery product line further encompasses the Leksell Vantage Stereotactic System for intracranial procedures and the Leksell Stereotactic System for minimally invasive interventions. Elekta AB (publ) was founded in 1972 and is headquartered in Stockholm, Sweden.
